Dividend, Aristocrats, select, group, S, P, 500, companies, raised, dividends, minimum, 25, consecutive, What, particularly, noteworthy, income, generating, equities, Dividend, Aristocrats, whole, beaten, broader, markets, well, vast, majority, sector, specific, exchange, traded, funds, terms, total, returns, capital, past, five, 
Despite, market, beating, performance, however, Dividend, Aristocrats, known, breathtaking, yields, For, instance, 57, companies, currently, esteemed, list, 40, sport, yields, less, 2, In, words, Dividend, Aristocrats, generally, great, place, unearth, top, notch, passive, income, opportunities, 
There, three, glaring, exceptions, general, trend, however, The, pharmaceutical, titan, AbbVie, NYSE, ABBV, telecom, giant, AT, T, NYSE, T, oil, gas, behemoth, ExxonMobil, NYSE, XOM, offer, forward, annual, dividend, yields, greater, 5, Which, high, yield, Dividend, Aristocrats, best, buy, right, Let, dig, deeper, find, 
When, comes, picking, dividend, stocks, three, key, criteria, consider, 
How, AbbVie, AT, T, ExxonMobil, stack, three, critical, factors, In, terms, forward, annual, dividend, yield, AbbVie, comes, 5, 6, tops, yields, AT, T, 5, 3, ExxonMobil, 5, 15, AbbVie, offers, highest, yield, among, Dividend, Aristocrats, 
How, sustainability, The, standard, metric, evaluate, sustainability, company, dividend, known, payout, ratio, expressed, dividends, per, share, divided, earnings, per, share, In, simplest, terms, higher, ratio, harder, company, maintain, dividend, current, levels, 
On, metric, ExxonMobil, takes, cake, trailing, 12, payout, ratio, 80, 2, AT, T, comes, second, place, 86, 4, AbbVie, hand, lags, far, behind, comparison, rather, worrisome, payout, ratio, 144, 5, AbbVie, dividend, payments, words, far, exceeding, net, income, prior, 12, period, 
The, payout, ratio, however, tell, full, story, AbbVie, set, merge, Botox, maker, Allergan, expected, provide, significant, boost, earnings, per, share, next, three, consecutive, AbbVie, top, line, free, cash, flow, also, line, get, nice, lift, trio, high, value, regulatory, approvals, Orilissa, Rinvoq, Skyrizi, coming, decade, 
The, point, AbbVie, danger, losing, Dividend, Aristocrat, status, In, fact, drugmaker, trouble, raising, dividend, next, despite, unsightly, trailing, payout, ratio, So, anything, AbbVie, AT, T, ExxonMobil, considered, fairly, safe, income, plays, 
How, valuation, AbbVie, hands, winner, metric, The, drugmaker, shares, currently, trading, paltry, eight, times, forward, looking, earnings, By, contrast, AT, T, shares, come, 10, 6, times, forward, looking, earnings, ExxonMobil, stock, sports, sky, valuation, 17, 45, times, forward, looking, earnings, 
While, three, Dividend, Aristocrats, arguably, worth, buying, AbbVie, stands, clear, winner, comparison, The, drugmaker, richest, payout, attractive, valuation, dividend, safe, long, haul, thanks, management, string, successful, business, development, activities, 

Before, consider, AT, T, Inc, want, hear, 
Investing, legends, Motley, Fool, Co, founders, David, Tom, Gardner, revealed, believe, 10, best, stocks, investors, buy, right, AT, T, Inc, one, 
